Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Overview
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Apollomics Inc
Bayer AG
DOT Therapeutics-1 Inc
Hanmi Pharmaceuticals Co Ltd
Jazz Pharmaceuticals Plc
Metagone Biotech Inc
Novartis AG
Redx Pharma Plc
Samjin Pharm Co Ltd
Verastem Inc
VG Life Sciences Inc
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Drug Profiles
(MG-005 + sorafenib) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(MG-010 + sorafenib) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APL-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belvarafenib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKI-27 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

 

List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Apollomics Inc, H1 2020
Pipeline by Bayer AG, H1 2020
Pipeline by DOT Therapeutics-1 Inc, H1 2020
Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020
Pipeline by Jazz Pharmaceuticals Plc, H1 2020
Pipeline by Metagone Biotech Inc, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Redx Pharma Plc, H1 2020
Pipeline by Samjin Pharm Co Ltd, H1 2020
Pipeline by Verastem Inc, H1 2020
Pipeline by VG Life Sciences Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020